Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Non Operating Income for 4 consecutive years, with $57000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 99.5% to $57000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, down 96.48% year-over-year, with the annual reading at -$19000.0 for FY2025, 100.01% down from the prior year.
  • Non Operating Income for Q4 2025 was $57000.0 at Day One Biopharmaceuticals, down from $4.5 million in the prior quarter.
  • The five-year high for Non Operating Income was $112.0 million in Q2 2024, with the low at -$23000.0 in Q1 2025.
  • Average Non Operating Income over 4 years is $9.6 million, with a median of $57000.0 recorded in 2025.
  • The sharpest move saw Non Operating Income tumbled 300.0% in 2023, then soared 746446.67% in 2024.
  • Over 4 years, Non Operating Income stood at $4.7 million in 2022, then crashed by 100.38% to -$18000.0 in 2023, then surged by 63511.11% to $11.4 million in 2024, then plummeted by 99.5% to $57000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $57000.0, $4.5 million, and -$19000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.